<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

    VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.

    Independent Study Data Supporting Clinical Use of Biodesix®’ Blood-Based Tests To Be Presented At CHEST Conference

    Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.

    Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy

    Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy

    Multi-Institutional Data Supporting Clinical Use of Biodesix’ Blood-Based Tests Presented Today at IASLC Conference

    Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference

    Wellmark BCBS of Iowa and South Dakota Provides Coverage for VeriStrat® Test

    Biodesix press release: Wellmark BCBS of Iowa and South Dakota provides coverage for VeriStrat® Test

    Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference

    Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference

    Independent Data Demonstrates Clinical Utility of Biodesix®’ Blood-Based Tests

    Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.

    Horizon Blue Cross Blue Shield of New Jersey Provides Coverage for Biodesix’ VeriStrat Test

    Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.

    Heinrich Roder to speak at 6th International Conference on Bioinformatics & Systems Biology

    Heinrich Roder will speak at the 6th International Conference on Bioinformatics and Systems Biology

    Biodesix Raises Follow-On Series F Financing

    Biodesix raises an additional $7 million in series F financing.